澤璟製藥(688266.SH):鹽酸吉卡昔替尼片治療重症斑禿III期臨牀試驗達到主要療效終點
格隆匯6月12日丨澤璟製藥(688266.SH)公佈,近日,公司自主研發的1類新藥鹽酸吉卡昔替尼片(曾用名:鹽酸傑克替尼片)治療重症斑禿的III期臨牀主試驗《鹽酸傑克替尼片治療重症斑禿患者的有效性和安全性的多中心、隨機、雙盲、安慰劑平行對照III期臨牀試驗》(方案編號:ZGJAK018)達到了主要療效終點,達到統計顯著性(p<0.0001)。公司將加快推進鹽酸吉卡昔替尼片治療重症斑禿患者適應症的上市進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.